Related references
Note: Only part of the references are listed.ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
David E. Gerber et al.
CANCER CELL (2010)
Clinical Implications of the Cancer Genome
Laura E. MacConaill et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer
Richard L. Schilsky et al.
ONCOLOGIST (2010)
Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
Emma C. Davies et al.
PLOS ONE (2009)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Russell A. Wilke et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing
Lecia V. Sequist et al.
ONCOLOGIST (2007)
Toxicogenomics and systems toxicology: Aims and prospects
MD Waters et al.
NATURE REVIEWS GENETICS (2004)
Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care
JS Ross et al.
DRUG DISCOVERY TODAY (2002)
Share Paper
